Understand the source comparison
Peptide Anxiolytic Comparison — Mechanism and Evidence
Selank GABAergic modulation via BDNF upregulation Intranasal Placebo-controlled trials in Russia (2008, 2013) showing 20–30% anxiety reduction Non-addictive; mild nasal irritation possible Best-evidenced anxiolytic peptide; intranasal route bypasses hepatic me
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selank
- GABAergic modulation via BDNF upregulation
- Intranasal
- Placebo-controlled trials in Russia (2008, 2013) showing 20–30% anxiety reduction
- Non-addictive; mild nasal irritation possible
- Best-evidenced anxiolytic peptide; intranasal route bypasses hepatic metabolism
- Cerebrolysin
- Neurotrophic factor mimicry; promotes synaptic plasticity
- IV or IM
- Austrian cortisol-reactivity studies (2014); no anxiety-specific RCTs
- Immunogenicity risk due to porcine origin
- Promising but requires clinical administration; not suitable for home use
- P21
- CREB-mediated neuroplasticity; fear extinction enhancement
- Preclinical only (rodent models); no human anxiety trials
- Unknown long-term neurotoxicity profile
- Research-stage only; mechanistic promise but no human safety data
- Thymalin
- Immune regulation; HPA axis stabilisation
- Subcutaneous
- Soviet-era research; no Western placebo-controlled trials
- Well-tolerated in clinical immune protocols
- Indirect anxiolytic via stress-axis regulation; limited anxiety-specific data